Skip to main content
. Author manuscript; available in PMC: 2023 Mar 15.
Published in final edited form as: Clin Cancer Res. 2022 Jul 21:ccr.22.1626. doi: 10.1158/1078-0432.CCR-22-1626

Figure 1. Suggested treatment algorithm for patients with R/R DLBCL after one prior line of systemic therapy ineligible for autologous stem cell transplant.

Figure 1.

Patients with R/R DLBCL after first-line treatment should be stratified by time to first relapse. Patients with refractory disease or disease that relapses within one year should proceed directly to CAR T-cell therapy. Late relapsers should be evaluated for candidacy for high dose chemotherapy and autologous stem cell transplant. Candidates should pursue salvage platinum-based immunochemotherapy followed by transplant in responders, while patients ineligible for transplant have multiple treatment options, including continuous tafasitamab plus lenalidomide, clinical trials, immunochemotherapy regimens, or polatuzumab vedotin with BR.

*Polatuzumab vedotin with BR is listed as a second-line treatment in the NCCN guidelines, though does not carry an FDA approval for this indication.

R/R, relapsed or refractory; DLBCL, diffuse large B-cell lymphoma; 1L, first-line; CAR T-cell, chimeric antigen receptor T-cell; ASCT, autologous stem cell transplant; BR, bendamustine and rituximab.